Metabolically inactive insulin analogue does not prevent autoimmune diabetes in NOD mice.

ABSTRACT:

Aims/hypothesis

Insulin is widely considered to be a driver antigen in type 1 diabetes in humans and in mouse models of the disease. Therefore, insulin or insulin analogues are candidates for tolerogenic drugs to prevent disease onset in individuals with risk of diabetes. Previous experiments have shown that autoimmune diabetes can be prevented in NOD mice by repeated doses of insulin administered via an oral, nasal or parenteral route, but clinical trials in humans have not succeeded. The hypoglycaemic activity of insulin is dose-limiting in clinical studies attempting tolerance and disease prevention. Here, we aimed to investigate the therapeutic potential of metabolically inactive insulin analogue (MII) in NOD mice.

Methods

The tolerogenic potential of MII to prevent auto

SUBMITTER: Gronholm J 

PROVIDER: S-EPMC5661969 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature